ATNM
Price
$1.40
Change
-$0.05 (-3.45%)
Updated
Nov 28, 01:59 PM (EDT)
Capitalization
45.23M
105 days until earnings call
Intraday BUY SELL Signals
GMAB
Price
$32.36
Change
+$0.44 (+1.38%)
Updated
Nov 28, 02:00 PM (EDT)
Capitalization
19.43B
69 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ATNM vs GMAB

Header iconATNM vs GMAB Comparison
Open Charts ATNM vs GMABBanner chart's image
Actinium Pharmaceuticals
Price$1.40
Change-$0.05 (-3.45%)
Volume$900
Capitalization45.23M
Genmab A/S ADS
Price$32.36
Change+$0.44 (+1.38%)
Volume$37.17K
Capitalization19.43B
ATNM vs GMAB Comparison Chart in %
ATNM
Daily Signal:
Gain/Loss:
GMAB
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
ATNM vs. GMAB commentary
Nov 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATNM is a Hold and GMAB is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 29, 2025
Stock price -- (ATNM: $1.45 vs. GMAB: $31.92)
Brand notoriety: ATNM and GMAB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATNM: 41% vs. GMAB: 53%
Market capitalization -- ATNM: $45.23M vs. GMAB: $19.43B
ATNM [@Biotechnology] is valued at $45.23M. GMAB’s [@Biotechnology] market capitalization is $19.43B. The market cap for tickers in the [@Biotechnology] industry ranges from $110.02B to $0. The average market capitalization across the [@Biotechnology] industry is $2.2B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATNM’s FA Score shows that 0 FA rating(s) are green whileGMAB’s FA Score has 0 green FA rating(s).

  • ATNM’s FA Score: 0 green, 5 red.
  • GMAB’s FA Score: 0 green, 5 red.
According to our system of comparison, GMAB is a better buy in the long-term than ATNM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATNM’s TA Score shows that 5 TA indicator(s) are bullish while GMAB’s TA Score has 5 bullish TA indicator(s).

  • ATNM’s TA Score: 5 bullish, 5 bearish.
  • GMAB’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, both ATNM and GMAB are a good buy in the short-term.

Price Growth

ATNM (@Biotechnology) experienced а +6.62% price change this week, while GMAB (@Biotechnology) price change was +4.42% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +8.81%. For the same industry, the average monthly price growth was +3.27%, and the average quarterly price growth was +75.56%.

Reported Earning Dates

ATNM is expected to report earnings on Mar 13, 2026.

GMAB is expected to report earnings on Feb 05, 2026.

Industries' Descriptions

@Biotechnology (+8.81% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GMAB($19.4B) has a higher market cap than ATNM($45.2M). GMAB YTD gains are higher at: 52.947 vs. ATNM (15.079). GMAB has higher annual earnings (EBITDA): 1.48B vs. ATNM (-43.43M). GMAB has more cash in the bank: 2.9B vs. ATNM (59.9M). ATNM has less debt than GMAB: ATNM (1.29M) vs GMAB (148M). GMAB has higher revenues than ATNM: GMAB (3.26B) vs ATNM (0).
ATNMGMABATNM / GMAB
Capitalization45.2M19.4B0%
EBITDA-43.43M1.48B-3%
Gain YTD15.07952.94728%
P/E RatioN/A14.17-
Revenue03.26B-
Total Cash59.9M2.9B2%
Total Debt1.29M148M1%
FUNDAMENTALS RATINGS
ATNM vs GMAB: Fundamental Ratings
ATNM
GMAB
OUTLOOK RATING
1..100
1624
VALUATION
overvalued / fair valued / undervalued
1..100
64
Fair valued
64
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9837
PRICE GROWTH RATING
1..100
6239
P/E GROWTH RATING
1..100
10080
SEASONALITY SCORE
1..100
8540

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ATNM's Valuation (64) in the Biotechnology industry is in the same range as GMAB (64) in the null industry. This means that ATNM’s stock grew similarly to GMAB’s over the last 12 months.

ATNM's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as GMAB (100) in the null industry. This means that ATNM’s stock grew similarly to GMAB’s over the last 12 months.

GMAB's SMR Rating (37) in the null industry is somewhat better than the same rating for ATNM (98) in the Biotechnology industry. This means that GMAB’s stock grew somewhat faster than ATNM’s over the last 12 months.

GMAB's Price Growth Rating (39) in the null industry is in the same range as ATNM (62) in the Biotechnology industry. This means that GMAB’s stock grew similarly to ATNM’s over the last 12 months.

GMAB's P/E Growth Rating (80) in the null industry is in the same range as ATNM (100) in the Biotechnology industry. This means that GMAB’s stock grew similarly to ATNM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATNMGMAB
RSI
ODDS (%)
Bullish Trend 3 days ago
83%
Bearish Trend 3 days ago
54%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
71%
Bearish Trend 3 days ago
75%
Momentum
ODDS (%)
Bullish Trend 3 days ago
78%
Bullish Trend 3 days ago
57%
MACD
ODDS (%)
Bullish Trend 3 days ago
69%
Bullish Trend 3 days ago
59%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
68%
Bullish Trend 3 days ago
62%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
89%
Bullish Trend 3 days ago
63%
Advances
ODDS (%)
Bullish Trend 3 days ago
71%
Bullish Trend 3 days ago
65%
Declines
ODDS (%)
Bearish Trend 9 days ago
89%
Bearish Trend 22 days ago
69%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 3 days ago
58%
Aroon
ODDS (%)
Bearish Trend 5 days ago
84%
Bearish Trend 3 days ago
72%
View a ticker or compare two or three
Interact to see
Advertisement
ATNM
Daily Signal:
Gain/Loss:
GMAB
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
AMDG30.052.19
+7.86%
Leverage Shares 2X Long AMD Daily ETF
TNA46.351.17
+2.59%
Direxion Daily Small Cap Bull 3X ETF
SPXX17.770.24
+1.37%
Nuveen S&P 500 Dynamic Overwrite Fund
XBOC33.220.14
+0.43%
Innovator US Eq Acclrtd 9 Bffr ETF™ Oct
VERS59.90N/A
N/A
ProShares Metaverse ETF

ATNM and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATNM has been loosely correlated with CRBU. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if ATNM jumps, then CRBU could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATNM
1D Price
Change %
ATNM100%
+3.57%
CRBU - ATNM
41%
Loosely correlated
+0.53%
RXRX - ATNM
41%
Loosely correlated
+0.92%
HOWL - ATNM
40%
Loosely correlated
+7.33%
CRSP - ATNM
40%
Loosely correlated
-0.50%
IPSC - ATNM
39%
Loosely correlated
+1.50%
More